Professor Richard Gilbert
Professor
| telephone | +61 3 9288 2574 |
| facsmilie | +61 3 9288 2581 |
richard.gilbert @ utoronto.ca |
Profile
Professor Richard Gilbert leads a research group looking at anti-fibrotic therapies for the treatment of heart and kidney failure; diabetes complications, particularly diabetic nephropathy and cardiomyopathy; hypertension and drug discovery. He has a major role in developing new international links with institutions and researchers in Canada. His primary academic appointment is at the University of Toronto.
University of Melbourne find an expert profile
Professional Activities:
Clinical Endocrinologist. Contributor to Australian Diabetes Society guidelines. NHMRC grant referee. Member: ANZ Society of Nephrology, European Diabetic Nephropathy Study Group. International Clinical Trials committee member. Provides consultative services to International Pharmaceutical Consultancies and Advisory Boards.
Qualifications
MBBS FRACP PhD
Major Grants
- "Effect of urotensin ii anatgonism in a rat model of pressure-overload hypertrophy" GLAXOSMITHKLINE Australia awarded 1/1/2006
- "Novel therapeutic strategies to reduce the burden of chronic heart failure" NHMRC program grant awarded 1/1/2005
- "Blockade of renin inhibition in experimental diabetic nephropathy: effects of aliskiren" Novartis Institute of Medical Research awarded 1/7/2005
- "Measurement of urinary tgf-beta in ly333531 treated patients" Eli Lilly Australia awarded 1/7/2005
- "Novel Therapies in Rats with Progressive Renal Disease" GLAXOSMITHKLINE Australia awarded 20/12/2002
- "Novel strategies for the early identification, prevention and treatment of the microvascular complications of diabetes" NHMRC/JDRF Special Program Grants in Type 1 Diabetes awarded 1/1/2002
Selected Publications
- Kelly, D.J., Gow, R., Zhang, Y, and Gilbert, R.E. (2004) Tranilast Attenuates Structural and Functional Aspects of Renal Injury in the Remnant Kidney Model. Journal of the American Society of Nephrology 15(10):2619-2629 IF = 7.371 (9)
- Kelly, D.J., Chanty, A., Gow, R.M., Zhang, Y. and Gilbert, R.E. (2005) Protein kinase C beta inhibition attenuates osteopontin expression, macrophage recruitment and tubulointerstitial injury in advanced experimental diabetic nephropathy. Journal of the American Society of Nephrology 16(6):1654-1660. Selected for editorial comments. IF = 7.371 (21)
- Kelly, D.J., Zhang, Y., Cox, A.J. and Gilbert, R.E. (2006) Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney International 69(11):1954-1960. IF = 4.773
- Advani, A*., Kelly, D.J.*, Advani, S.L., Cox, A.J., Thai, K., Zhang, Y., White, K.E., Gow, R.M., Marshall, S.M., Steer, B.M., Marsden, P.A., Rakoczy, P.E. and Gilbert, RE. (2007) Role of vascular endothelial growth factor in maintaining renal structure and function under normotensive and hypertensive conditions. PNAS 104(36):14448-14453. *Equal first author IF = 9.643 (0)
- Kelly, D.J., Zhang, Y., Moe, G., Naik, G. and Gilbert, R.E. (2007) Aliskiren, a novel renin inhibitor, is renoprotective in advanced diabetic nephropathy in rats. Diabetologia 50(11):2398-2404. IF = 5.247 (0)